May 26, 2017
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflamm"...



How Supplied


AllerNaze (triamcinolone acetonide nasal spray) is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 12 years of age or older.


The recommended starting dose of AllerNaze (triamcinolone acetonide nasal spray) for most patients is 200 mcg per day given as 2 sprays (approximately 50 mcg/spray) in each nostril once a day. The maximum dose should not exceed 400 mcg per day. If the 400 mcg dose is used, it may be given either as a once a day dosage (4 sprays in each nostril) or divided into two daily doses of two sprays/nostril twice a day.

The nasal spray pump must be primed before AllerNaze (triamcinolone acetonide nasal spray) is used for the first time. To prime the pump, press down on the shoulder of the white nasal applicator using your forefinger and middle finger while supporting the base of the bottle with your thumb. Press down and release the pump until it sprays 3 times or until a fine mist is observed (see DIRECTIONS FOR USE).

Some patients may obtain relief of symptoms sooner when started on a 400 mcg per day dose of AllerNaze (triamcinolone acetonide nasal spray) than with 200 mcg per day. Onset of significant relief of nasal symptoms was seen within two days after starting treatment at 400 mcg once daily. A starting dose of 400 mcg per day may be considered in patients when starting therapy with AllerNaze (triamcinolone acetonide nasal spray) in cases where a faster onset of relief is desirable. Generally, maximum relief of symptoms may take several days or up to one week to occur.

After symptoms have been brought under control, patients should be titrated to the minimum effective dose to reduce the possibility of adverse effects.

If relief of symptoms is not achieved after 14-21 days of AllerNaze (triamcinolone acetonide nasal spray) therapy given in an adequate dose, AllerNaze (triamcinolone acetonide nasal spray) should be discontinued and alternative diagnosis and therapies considered.

AllerNaze (triamcinolone acetonide nasal spray) is not recommended for use in persons under 12 years of age since its safety and effectiveness have not been established in this age group.

Directions For Use

Illustrated patient instructions for use accompany each package of AllerNaze (triamcinolone acetonide nasal spray) .


Each 15 mL bottle of AllerNaze (triamcinolone acetonide nasal spray) (NDC 16781-117-15) contains 7.5 mg (0.50 mg/mL) of triamcinolone acetonide, USP and is fitted with a meter pump with white nasal applicator, teal blue dust cover and teal blue locking clip sealed in a foil pouch. The unit delivers 120 metered actuations and comes with a patient' instructions for use leaflet. The bottle should be discarded when the labeled number of actuations have been reached even though the bottle is not completely empty.

Keep out of reach of children.

Store at controlled room temperature: 20°-25°C (68°-77°F). Protect from freezing.

Use AllerNaze (triamcinolone acetonide nasal spray) within 2 months after opening of the protective foil pouch or before expiration date, whichever comes first.

Collegium Pharmaceutical, Incorporated, Cumberland, RI 02864-1788. Tel: 1-401-762-2000.,

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 2/24/2009

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Allergies & Asthma

Improve treatments & prevent attacks.